Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05791201 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria revised Site details revised at 1 of 16 sites Show 1 more changeShow less
    • Site details revised at 1 of 16 sites
  2. Re-verified, no change to tracked fieldsv25
  3. Primary and study completion pushed from May 29, 2026 to Mar 12, 2027 Primary endpoint(s) modified · Secondary endpoints shortened, about 37 wordsv24 Show 2 more changesShow less
    • Primary endpoint(s) modified
    • Secondary endpoints shortened, about 37 words

    See this version in full on ClinicalTrials.gov ↗

  4. 5 versions Re-verified since May 21, 2025, no change to tracked fieldsv19-v23
  5. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 17 to confirmed 7 · Primary and study completion dates: May 2026 to May 29, 2026 · Eligibility criteria shortened, about 7 words · 1 morev18 Show 4 more changesShow less
    • Enrollment target: estimated 17 to confirmed 7
    • Primary and study completion dates: May 2026 to May 29, 2026
    • Eligibility criteria shortened, about 7 words
    • Site details revised at 16 of 16 sites

    See this version in full on ClinicalTrials.gov ↗

Show 16 earlier versionsHide 16 earlier versions
  1. Study sites: 15 to 16v17
  2. Re-verified, no change to tracked fieldsv16
  3. Study sites: 13 to 15v15
  4. Study sites: 12 to 13v14
  5. Eligibility criteria expanded, about 3 wordsv13 See this version in full on ClinicalTrials.gov ↗
  6. Study sites: 11 to 12v12
  7. Study sites: 10 to 11v11
  8. Study sites: 9 to 10v10
  9. Study sites: 8 to 9v9
  10. Study sites: 7 to 8v8
  11. Re-verified, no change to tracked fieldsv7
  12. Study sites: 6 to 7v6
  13. Study sites: 5 to 6v5
  14. Study sites: 3 to 5v4
  15. Study sites: 1 to 3v3
  16. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Apr 2023 to May 16, 2023v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 2023 to May 16, 2023
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
Trial Details
NCT Number NCT05791201
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Type 1 Diabetes
Enrollment 7 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov